Retatrutide and Anavar (Oxandrolone)
No clinical trial has studied this combination. Oxandrolone is a Schedule III controlled substance. Retatrutide is not FDA approved. All rationale for combining them is anecdotal.
This page reviews what is known about combining retatrutide with oxandrolone (Anavar): the regulatory status of each compound, what human evidence exists, theoretical rationale discussed in online communities, and the risks that are known or plausible.
What Each Compound Is
Why People Search for This Combination
Bodybuilding and fitness communities discuss this combination for cutting cycles — using retatrutide's aggressive fat loss while using oxandrolone to preserve or build lean mass. The rationale draws on retatrutide's documented fat mass reduction in trials and oxandrolone's known anabolic effects. No clinical evidence supports this combination.
Human Evidence
No published clinical trial has studied retatrutide combined with oxandrolone. The TRIUMPH Phase 3 trials excluded participants on anabolic steroids. Retatrutide's Phase 2 trial (Jastreboff et al., NEJM 2023) showed up to 24.2% mean weight loss at 48 weeks at the highest dose, with fat mass reduction as the primary driver. Lean mass changes were documented but not the primary endpoint. Oxandrolone has established clinical evidence for muscle preservation in specific medical contexts (burns, HIV wasting, hypogonadism) but not in combination with GLP-1 class agents.
Theoretical Rationale
The theoretical rationale is that retatrutide's appetite suppression and fat oxidation effects could be combined with oxandrolone's anabolic signaling to produce fat loss while preserving or increasing lean mass. This is a pharmacologically plausible hypothesis but has not been tested. The interaction between GLP-1/GIP/glucagon receptor agonism and androgen receptor signaling is unstudied in humans.
Known and Plausible Risks
- Retatrutide: GI adverse events (nausea, vomiting, diarrhea), dose-dependent; heart rate increase; gallbladder effects; class-level precautions for thyroid C-cell tumors and pancreatitis
- Oxandrolone: Liver toxicity (oral anabolic steroid), cardiovascular risk (lipid changes), hormonal suppression, virilization in women
- Combined: Unknown interaction risks; no safety data for the combination exists
Body Composition Considerations
Retatrutide's Phase 2 data showed significant fat mass reduction with some lean mass loss — a pattern common to aggressive caloric restriction. Oxandrolone is used clinically to attenuate lean mass loss in catabolic states. Whether oxandrolone would meaningfully preserve lean mass during retatrutide-induced weight loss is unknown. No body composition data exists for the combination.
What People Are Discussing Online
Reddit communities (r/Peptides, r/sarmssourcetalk, r/PEDs) discuss this combination primarily in the context of cutting cycles. Common claims include that oxandrolone prevents the lean mass loss seen with GLP-1 agents and that the combination produces superior body recomposition versus either compound alone. These claims are anecdotal and not supported by clinical evidence.
Regulatory and Legal Context
Oxandrolone is a Schedule III controlled substance under the Controlled Substances Act. Non-medical use is illegal in the United States. Retatrutide is not FDA approved and is available only through clinical trials or compounding pharmacies (with significant regulatory uncertainty). Combining a Schedule III controlled substance with an unapproved investigational drug outside a supervised clinical context carries significant legal and medical risks.
Frequently Asked Questions
No. No published clinical trial has studied retatrutide combined with oxandrolone. The TRIUMPH Phase 3 trials excluded participants on anabolic steroids.
Oxandrolone is a Schedule III controlled substance. Non-medical use is illegal in the US. Retatrutide is not FDA approved. Any combination use outside a supervised clinical context carries significant legal and medical risks.
Online communities discuss this combination for cutting cycles — using retatrutide for fat loss while using oxandrolone to preserve lean mass. This rationale is anecdotal and not supported by clinical evidence.
Ready to Start Your Physician Review?
$477 one-time payment. No membership. No recurring billing. No charge unless approved.
START PHYSICIAN REVIEW